DESC:Technical field:
The invention relates to Nutraceutical/Therapeutical compositions comprising
Cinnamic acid derivatives with sucrose isomers useful as nootropic performance
enhancers and also for the pain management. The invention further relates to
process for the preparation of the said compositions and methods of use thereof.
Background and prior art:
HydroxyCinnamic acids are phenolic acid compounds which are present in many
plants either in free state or as derivatives such as esters or amides and also known
to possess potent antioxidant, antitumor, antidepressant, cytoprotective
neuroinflammation in neurodegenerative diseases, anti-inflammatory and
antiarthritic properties. They also prevent insulin resistance, cardiovascular
disease, renal dysfunctions, diabetes, dyslipidemia and improves liver functions.
Furthermore, esters of hydroxy Cinnamic acids have potential therapeutic
applications in experimental diabetes and hyperlipidemia, lowering lipid profile,
improving brain functions and pain management.
Naturally occurring esters of hydroxy Cinnamic acids are known to reduce the
anxiety and stress by regulating GABA receptors. Cinnamic acids esters are
known to increase the firing of neurons which leads to the improvement of brain
function and memory. WO2020176432A1 discloses a method for inhibiting the
progression of glycine encephalopathy comprising, administering to a patient in
need thereof an therapeutically effective amount of a pharmaceutical composition
comprising Cinnamic acid.
CN107624068A discloses method for treating hypertension using a combination
comprising Cinnamic acid and zinc to individual in need thereof.
Isomers of sugars are also involved in various metabolic and signaling pathways,
including those that contribute to antioxidant properties, scavengers of hydroxyl
radicals, their effectiveness against inflammation, as neuroprotectant. These
3
sugars also have many physiological and cardiometabolic benefits, ranging from
weight loss to improving glycemic control and reducing insulin resistance. The
health benefits of rare sugars in humans have begun to accrue for a number of rare
sugars, including allulose, tagatose, isomaltulose, arabinose, and trehalose.
Currently, naturally occurring sucrose isomers, trehalose, trehalulose, turanose,
leucrose, and isomaltulose are considered to be possible alternatives to sucrose
due to their potential cognitive benefits like positive effects on mood, improved
episodic and working memory, improved attention speed. In addition, sucrose
isomers also contribute in fat oxidation in energy metabolism; improved physical
performance; protection against hypoglycemia during exercise.
Evidence of the facilitation of episodic memory suggests a specific enhancing
effect of sucrose isomers intake on cognitive domains associated with the function
of the hippocampus. In support of this, facilitative effects have also been reported
for additional hippocampal-dependent cognitive functions like recognition
memory; visuospatial memory and visuospatial functioning.
The antioxidant activity of the rare sugar D-allose by eliminating the hydroxyl
radicals has recently been reported and the effect is close to the extent D glucose
scavenge the hydroxyl radicals. Cancer and tumor inhibition is considered to be
the most important property of D-allose. D-allose has been reported to be effective
against various human cancers, such as ovarian, cervical and skin, hepatocellular
and prostate cancers. Leukemia, head and neck cancer, pancreas, and lung cancer
are also inhibited by D allose.
The anti-oxidant activity of D-allulose persists over a long period of storage, and
is highly soluble compared to D fructose or D glucose. D-allulose showed
hypoglycemic properties and therapeutic effects on type 2 diabetes. It also has
anti-obesity and antihyperlipidemic effects. Furthermore, D-allulose can be used
against inflammation and atherosclerotic diseases, as a neuroprotectant.
4
D-tagatose has antioxidant and cryoprotectant properties in addition to its ability
to assist in body weight reduction. D-tagatose has also therapeutic potential in
type 2 diabetes management, since it improves glycemic control.
Although the applications of rare sugars in human nutrition and medicine have
been widely studied, their potential use for sustainable food production, and
application in agriculture is scantly reported.
Despite the potential benefit of these natural products there exist hardly any
literature available in the prior art or a product available in the market for human
application which offers the synergistic properties of Cinnamic acid and isomers
of sugars in general and sucrose in particular.
Accordingly, a provision of a composition comprising the combination of
Cinnamic acid and its derivatives with sugar isomers have become an objective of
the present invention owing to their structural diversity, together with distinctive
and remarkable pharmacological and pharmacodynamic actions, such as
antidepression, anticancer, antioxidant, anti-inflammatory and antiviral activities.
Therefore, the inventors felt that there is a need in the art to develop novel
formulation(s) which will help in improving focus and learning, reduce anxiety,
improves physical and mental performance, effectively manage inflammatory
disease and pain and also act as scavengers of reactive oxygen species thereby
offering cell protection.
Summary of the invention:
In line with the above objective, the present invention provides unique dual role of
novel Nutraceutical/Therapeutical compositions/formulations comprising
Cinnamic acids or its derivatives with sucrose isomers useful as nootropic
performance enhancers.
5
Accordingly, the invention provides novel compositions/formulations comprising
Cinnamic acid derivatives with Sucrose isomers having nutritive/therapeutic
value, wherein, the Cinnamic acid or its derivatives present in an amount of 2%-
90% w/w and sucrose isomers present in an amount of 10-90% w/w.
In another aspect, the composition also contains suitable excipients, which can be
selected from the group consisting of binders, diluents, lubricants, stabilizers,
solubilizers, sustained release polymers, suitable coloring agents, taste enhancers,
etc., to obtain desired formulation properties.
In a further aspect, the Nutraceutical/Therapeutical composition can be formulated
using suitable excipients into either oral solid, liquid or suspension formulations
using suitable techniques.
In yet another aspect, the invention provides methods of improving focus and
learning, reducing anxiety, improving physical and mental performance,
effectively managing inflammatory disease & pain and for scavenging the reactive
oxygen species thereby offering cell protection in a subject, which method
comprises treating the said subject with a composition comprising Cinnamic
Acids or its derivatives with Sucrose Isomers in therapeutically effective amounts.
Detailed description of the invention:
The invention will now be described in detail in connection with certain preferred
and optional embodiments, so that various aspects thereof may be more fully
understood and appreciated.
Accordingly, the present invention provides novel Nutraceutical/Therapeutical
compositions/formulations comprising Cinnamic acids or its derivatives with
Sucrose isomers useful as nootropic performance enhancers and also for the pain
management.
6
The term “Nutraceutical” refers to a hybrid of ‘nutrition’ and ‘pharmaceutical’.
Nutraceuticals, in broad, are ‘functional food’ or part of “food playing a
significant role in modifying and maintaining normal physiological function that
maintains health of human beings”.
Accordingly, the invention provides novel nutraceutical
compositions/formulations comprising Cinnamic acid derivatives with sugar
isomers having nutritive/therapeutic value, wherein, the Cinnamic acid or its
derivatives present in an amount of 2%-90% w/w and Sucrose isomers present in
an amount of 10-90% w/w and nutraceutical/therapeutic excipient in an amount of
5-90%.
In another aspect, the Nutraceutical/Therapeutical compositions of the present
invention can also be useful for pain management.
In one of the embodiments, the Cinnamic acid derivatives are selected from
Hydroxy Cinnamic acids, its esters and amides.
In an embodiment, the Hydroxy Cinnamic acid derivatives (CA) are selected from
Hydroxy Cinnamic acid, Ferulic acid, Caffeic acid, Sinapic acid, Chlorogenic
Acid, Rosmarinic acid, Syringic acid, p-Coumaric acid etc.
In another embodiment, the derivatives of Cinnamic acid esters are selected from
alkyl/aralkyl alcohols esterified with appropriate Cinnamic acids having general
formula CA-CO-OR where CA = Cinnamic Acid and R= C1-C22 alkyl chain; Ph-
CH2CH2- and CA-CO-O(CH)nO-CO-CA where n = 1-10. Esters of Cinnamic
acids also includes branched alkyl groups such as Isopropyl, Iso-butyl cinnamate,
Isopentyl, Phenylethyl etc.
7
In yet another embodiment, the derivatives of Cinnamic acid amides are selected
from amides having general formula CA-CO-NHR where CA-CO- = Cinnamic
Acid and NHR = Tyramine, Phenethylamine, Serotonin or Dopamine
In another embodiment, the isomers of sugars are selected from monosaccharides
or disaccharides. Isomers of monosaccharides sugars are selected from D Allose,
D Allulose and D Tagatose.
The isomers of disaccharides sugars are selected from Trehalulose, Turanose,
Leucrose and Isomaltulose.
In another embodiment, the composition also contains suitable
nutraceutical/therapeutic excipients, which can be selected from the group
consisting of binders, diluents, lubricants, stabilizers, solubilizers, sustained
release polymers, suitable coloring agents, taste enhancers, etc.
In a further embodiment, the composition can be formulated using suitable
excipients into either oral solid, liquid or suspension formulations.
In another embodiment, the nutraceutical/ therapeutic composition of the present
may be prepared by a process known in the art comprising adding suitable
excipients to the active ingredients Cinnamic acid derivatives along with sucrose
isomers in suitable proportions.
Accordingly, the process for preparation of the present composition comprises;
i. Adding cinnamic acid derivatives in an amount of 2%-90% w/w to
the aqueous solution of the sugar isomers in an amount of 10%-
90% w/w;
ii. Adding suitable nutraceutical excipients in an amount of 5- 90%
w/w to the solution of step (i); and
iii. Agitating the solution of step (ii) to avoid heat-induced inversion
of sucrose followed by drying to obtain the desired composition.
8
In yet another embodiment, the invention provides method of enhancing the brain
performance, reducing anxiety, improving the learning and focus without anxiety
in a subject which method comprises treating the said subject with a composition
comprising Cinnamic Acids or its derivatives with Sucrose Isomers in
nutraceutically effective amounts.
In yet another embodiment, the invention provides method of treating
inflammation in a subject which method comprises treating the said subject with a
composition comprising Cinnamic Acids or its derivatives with Sucrose Isomers
in therapeutically effective amounts, wherein the inflammation is selected from
the inflammation related to the COX 2.
The term “nutraceutically effective amount” means an amount that renders desired
nutritional and therapeutic benefit of the or outcome in alleviating or reducing or
controlling the progression of the disease.
The following examples are presented to further explain the invention with
experimental conditions, which are purely illustrative and are not intended to limit
the scope of the invention.
Examples:
Illustrative Formulations:
The formulations listed below are set forth for illustrative purposes only, and
should not be used to limit the proper construction of the claims in any manner
whatsoever. In the formulations nutraceutical exceipient percentage varies from 5-
90%
Illustrative formulations are set forth below:
9
Example 1: Formulation of Cinnamic acid derivatives with mono and
disaccharides
S.NO Sugar Percentage of Sugar Cinnamic Acid
derivative
Percentage of Cinnamic
acid
1 D-allose 10-90 Cinnamic acid 2-90
Ferulic acid
Caffeic acid
Sinapic acid
Chlorogenic Acid
Rosmarinic acid
Syringic acid
p-Coumaric acid
2 D-Allulose
10-90 Cinnamic acid 2-90
Ferulic acid
Caffeic acid
Sinapic acid
Chlorogenic Acid
Rosmarinic acid
Syringic acid
p-Coumaric acid
3 D-Tagatose 10-90 Cinnamic acid
Ferulic acid
Caffeic acid 2-90
Sinapic acid
Chlorogenic Acid
Rosmarinic acid
Syringic acid
p-Coumaric acid
4 Trehalulose
10-90 Cinnamic acid 2-90
Ferulic acid
Caffeic acid
Sinapic acid
Chlorogenic Acid
Rosmarinic acid
Syringic acid
p-Coumaric acid
5 Turanose 10-90 Cinnamic acid 2-90
Ferulic acid
Caffeic acid
Sinapic acid
10
Chlorogenic Acid
Rosmarinic acid
Syringic acid
p-Coumaric acid
6 Leucrose 10-90 Cinnamic acid 2-90
Ferulic acid
Caffeic acid
Sinapic acid
Chlorogenic Acid
Rosmarinic acid
Syringic acid
p-Coumaric acid
7 Isomaltulose 10-90 Cinnamic acid 2-90
Ferulic acid
Caffeic acid
Sinapic acid
Chlorogenic Acid
Rosmarinic acid
Syringic acid
p-Coumaric acid
Example 2: Formulation of Cinnamic acid ester derivatives with mono and
disaccharides
S.NO Sugar Percentage of
Sugar
Cinnamic Acid ester
derivative
Percentage of Cinnamic
acid
1 D-allose 10-90 n-Hexadecyl Cinnamte 2-90
n-Octadecyl cinnamte
n-Eicosyl cinnamate
n-Docosyl cinnamate
n-Hexadecyl ferulate
n-Octadecyl ferulate
n-Eicosyl ferulate 2-90
n-Docosyl ferulate
n-Hexadecyl caffeate
n-Octadecyl caffeate
n-Eicosyl caffeate
n-Docosyl caffeate
n-Hexadecyl coumarate
11
n-Octadecyl coumarate
n-Eicosyl coumarate
n-Docosyl coumarate
Caffeic acid phenethyl
ester
2 D-Allulose 10-90 n-Hexadecyl cinnamte 2-90
n-Octadecyl cinnamte
n-Eicosyl cinnamate
n-Docosyl cinnamate
n-Hexadecyl ferulate
n-Octadecyl ferulate
n-Eicosyl ferulate
n-Docosyl ferulate
n-Hexadecyl caffeate
n-Octadecyl caffeate
n-Eicosyl caffeate
n-Docosyl caffeate
n-Hexadecyl coumarate
n-Octadecyl coumarate
n-Eicosyl coumarate
n-Docosyl coumarate
Caffeic acid phenethyl
ester
3 D-Tagatose 10-90 n-Hexadecyl cinnamte 2-90
n-Octadecyl cinnamte
n-Eicosyl cinnamate
n-Docosyl cinnamate
n-Hexadecyl ferulate
n-Octadecyl ferulate
n-Eicosyl ferulate
n-Docosyl ferulate
n-Hexadecyl caffeate
n-Octadecyl caffeate
n-Eicosyl caffeate
n-Docosyl caffeate
n-Hexadecyl coumarate
n-Octadecyl coumarate
12
n-Eicosyl coumarate
Caffeic acid phenethyl
ester
n-Docosyl coumarate
4 Trehalulose
10-90 n-Hexadecyl cinnamte 2-90
n-Octadecyl cinnamte
n-Eicosyl cinnamate
n-Docosyl cinnamate
n-Hexadecyl ferulate
n-Octadecyl ferulate
n-Eicosyl ferulate
n-Docosyl ferulate
n-Hexadecyl caffeate
n-Octadecyl caffeate
n-Eicosyl caffeate
n-Docosyl caffeate
n-Hexadecyl coumarate
n-Octadecyl coumarate
n-Eicosyl coumarate
Caffeic acid phenethyl
ester
n-Docosyl coumarate
5 Turanose 10-90 n-Hexadecyl cinnamte 2-90
n-Octadecyl cinnamte
n-Eicosyl cinnamate
n-Docosyl cinnamate
n-Hexadecyl ferulate
n-Octadecyl ferulate
n-Eicosyl ferulate
n-Docosyl ferulate
n-Hexadecyl caffeate
n-Octadecyl caffeate
n-Eicosyl caffeate
n-Docosyl caffeate
n-Hexadecyl coumarate
n-Octadecyl coumarate
n-Eicosyl coumarate
13
Caffeic acid phenethyl
ester
n-Docosyl coumarate
6 Leucrose
10-90 n-Hexadecyl cinnamte 2-90
n-Octadecyl cinnamte
n-Eicosyl cinnamate
n-Docosyl cinnamate
n-Hexadecyl ferulate
n-Octadecyl ferulate
n-Eicosyl ferulate
n-Docosyl ferulate
n-Hexadecyl caffeate
n-Octadecyl caffeate
n-Eicosyl caffeate
n-Docosyl caffeate
n-Hexadecyl coumarate
n-Octadecyl coumarate
n-Eicosyl coumarate
Caffeic acid phenethyl
ester
n-Docosyl coumarate
7 Isomaltulose
10-90 n-Hexadecyl cinnamte 2-90
n-Octadecyl cinnamte
n-Eicosyl cinnamate
n-Docosyl cinnamate
n-Hexadecyl ferulate
n-Octadecyl ferulate
n-Eicosyl ferulate
n-Docosyl ferulate
n-Hexadecyl caffeate
n-Octadecyl caffeate
n-Eicosyl caffeate
n-Docosyl caffeate
n-Hexadecyl coumarate
n-Octadecyl coumarate
n-Eicosyl coumarate
Caffeic acid phenethyl
14
ester
n-Docosyl coumarate
Example 3: Formulation of Cinnamic acid amide derivatives with mono and
disaccharides
S.NO Sugar Percentage of
Sugar
Cinnamic Acid
amide derivative
Percentage of Cinnamic
acid
10 D-allose 10-90 Cinnamyl tyramine 2-90
Feruloyl tyramine
Coumaroyl tyramine
Caffeoyl tyramine
Cinnamyl serotonin
Feruloyl serotonin
Coumaroyl serotonin
Caffeoyl serotonin
Caffeic acid
phenethyl amide
Cinnamyl dopamine
Feruloyl dopamine
Coumaroyl
dopamine
Caffeoyl dopamine
2 D-Allulose
10-90 Cinnamyl tyramine 2-90
Feruloyl tyramine
Coumaroyl tyramine
Caffeoyl tyramine
Cinnamyl serotonin
Feruloyl serotonin
Coumaroyl serotonin
Caffeoyl serotonin
Caffeic acid phenethyl
amide
Cinnamyl dopamine
Feruloyl dopamine
Coumaroyl dopamine
Caffeoyl dopamine
15
3 D-Tagatose 10-90 Cinnamyl tyramine 2-90
Feruloyl tyramine
Coumaroyl tyramine
Caffeoyl tyramine
Cinnamyl serotonin
Feruloyl serotonin
Coumaroyl serotonin
Caffeoyl serotonin
Caffeic acid phenethyl
amide
Cinnamyl dopamine
Feruloyl dopamine
Coumaroyl dopamine
Caffeoyl dopamine
4 Trehalulose
10-90 Cinnamyl tyramine 2-90
Feruloyl tyramine
Coumaroyl tyramine
Caffeoyl tyramine
Cinnamyl serotonin
Feruloyl serotonin
Coumaroyl serotonin
Caffeoyl serotonin
Caffeic acid phenethyl
amide
Cinnamyl dopamine
Feruloyl dopamine
Coumaroyl dopamine
Caffeoyl dopamine
5 Turanose 10-90 Cinnamyl tyramine 2-90
Feruloyl tyramine
Coumaroyl tyramine
Caffeoyl tyramine
Cinnamyl serotonin
Feruloyl serotonin
Coumaroyl serotonin
Caffeoyl serotonin
Caffeic acid phenethyl
amide
Cinnamyl dopamine
Feruloyl dopamine
Coumaroyl dopamine
Caffeoyl dopamine
6 Leucrose 10-90 Cinnamyl tyramine 2-90
Feruloyl tyramine
Coumaroyl tyramine
Caffeoyl tyramine
16
Cinnamyl serotonin
Feruloyl serotonin
Coumaroyl serotonin
Caffeoyl serotonin
Caffeic acid phenethyl
amide
Cinnamyl dopamine
Feruloyl dopamine
Coumaroyl dopamine
Caffeoyl dopamine
7 Isomaltulose 10-90% Cinnamyl tyramine 2-90%
Feruloyl tyramine
Coumaroyl tyramine
Caffeoyl tyramine
Cinnamyl serotonin
Feruloyl serotonin
Coumaroyl serotonin
Caffeoyl serotonin
Caffeic acid phenethyl
amide
Cinnamyl dopamine
Feruloyl dopamine
Coumaroyl dopamine
Caffeoyl dopamine
Cinnamyl tyramine
Example 4: General procedure for the preparation of formulation of
cinnamic acid derivatives with sucrose isomers
To the aqueous solution of D-Allose, D-Allulose and D-Tagatose, L-Arabinose,
Trehalulose, Turanose, Leucrose and Isomaltulose (90-10% w/w) was added,
Cinnamic acid/ester/amide (2-90% w/w), followed by the addition of suitable
nutraceutical excipients (5- 90% w/w). The composition was agitated at room
temperature to avoid heat-induced inversion of sucrose for 1.0-2.0 h. The resulting
solution/suspension was packed for usage.
Example 4a:
25 g of Trehalulose was added to 100 mL purified water under stirring at room
temperature. Slowly added 0.1 g of n-Docosyl Coumarate and allowed to stir for
17
30 minutes followed by the addition of 5 g of calcium stearate. The resulting
solution was stirred for 1 hr at room temperature and dried.
Example 4b:
25 g of Isomaltulose was added to 100 mL purified water under stirring at room
temperature. Slowly added 0.5 g of n-Octadecyl ferulate and allowed to stir for
30 minutes followed by the addition of 5 g of calcium stearate. The resulting
solution was stirred for 1 hr at room temperature and evaporated to dryness.
Example 4c:
25 g of D-Allulose was added to 100 mL purified water under stirring at room
temperature. Slowly added 1 g of n-trans-Caffeoyl-tyramine and allowed to stir
for 30 minutes followed by the addition of 5 g of calcium stearate. The resulting
solution was stirred for 1 hr at room temperature and freeze dried. ,CLAIMS:A composition comprising Cinnamic acid derivatives with sucrose/sugar
isomers having nutritive/therapeutic value, wherein, the Cinnamic acid
derivatives is present in an amount of 2%-90% w/w and sucrose/ sugar
isomers present in an amount of 10%-90% w/w.
2. The composition as claimed in Claim 1, wherein the said composition
comprises nutraceutical/therapeutic excipients in an amount of 5-90%.
3. The composition as claimed in Claim 1, wherein the Cinnamic acid
derivatives are selected from Hydroxy Cinnamic acids, its esters and
amides.
4. The composition as claimed in Claim 3, wherein the Hydroxy Cinnamic
acid derivatives (CA) are selected from Hydroxy Cinnamic acid, Ferulic
acid, Caffeic acid, Sinapic acid, Chlorogenic Acid, Syringic acid p-
Coumaric acid and the like.
5. The composition as claimed in Claim 3, wherein the derivatives of
Cinnamic acid esters are selected from alkyl/aralkyl alcohols esterified
with Cinnamic acids having general formula CA-CO-OR wherein CA
represents Cinnamic Acid and R represents C1-C22 alkyl chain, Ph-
CH2CH2- or CA-CO-O(CH)nO-CO-CA; n = 1-10 wherein the esters of
Cinnamic acids includes branched alkyl groups such as Isopropyl, Isobutyl
cinnamate, Isopentyl and the like.
6. The composition as claimed in Claim 3, wherein the derivatives of
Cinnamic acid amides are selected from amides having general formula
CA-CO-NHR wherein CA represents Cinnamic Acid and NHR represents
Tyramine, Serotonin, Dopamine, Phenethylamine.
7. The compositions as claimed in Claim 1, wherein the isomers of sugars are
selected from monosaccharides or disaccharides.
8. The composition as claimed in Claim 7, wherein the isomers of
monosaccharides are selected from D Allose, D Allulose and D Tagatose.
9. The compositions as claimed in Claim 7, wherein isomers of disaccharides
are selected from Trehalulose, Turanose, Leucrose and Isomaltulose.
19
10. The composition as claimed in Claim 2, wherein the composition may
contain nutraceutical/therapeutic excipients selected from the group
consisting of binders, diluents, lubricants, stabilizers, solubilizers,
sustained release polymers, coloring agents, taste enhancers and the like.
11. The composition as claimed in any one of the Claims 1 to 10, wherein the
composition may be formulated into either oral solid, liquid or
suspensions.
12. The composition comprising Cinnamic acid derivatives with sucrose
isomers as claimed in any one of the preceding claims 1 to 11 as
nutraceutical/therapeutic composition.
13. A process for preparation of the composition comprising;
i. Adding cinnamic acid derivatives in an amount of 2%-90% w/w to
the aqueous solution of the sugar isomers in an amount of 10%-
90% w/w;
ii. Adding suitable nutraceutical excipients in an amount of 5- 90%
w/w to the solution of step (i); and
iii. Agitating the solution of step (ii) to avoid heat-induced inversion
of sucrose followed by drying to obtain the desired composition.
14. A method of enhancing the brain performance, reducing anxiety,
improving the learning and focus without anxiety in a subject wherein the
method comprises providing said subject with a composition comprising
Cinnamic Acids or its derivatives with Sucrose Isomers as claimed in any
one of the preceding claims in nutraceutically effective amount.
15. A method of treating inflammation in a subject wherein the method
comprises providing said subject with a composition comprising Cinnamic
Acids or its derivatives with Sucrose Isomers as claimed in any one of the
preceding claims in therapeutically effective amounts, wherein the
inflammation is selected from the inflammation related to the COX 2.
16. The composition comprising Cinnamic acid derivatives with sucrose
isomers as claimed in any one of the preceding claims for enhancing the
20
brain performance, reducing anxiety, improving the learning and focus
without anxiety.
17. The composition comprising Cinnamic acid derivatives with sucrose
isomers as claimed in any one of the preceding claims for treating
inflammation, wherein the inflammation is selected from the inflammation
related to the COX 2.
18. The composition comprising Cinnamic acid derivatives with sucrose
isomers as claimed in any one of the preceding claims useful as nootropic
performance enhancers and for the pain management.